Alkermes (NASDAQ:ALKS – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.670. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.
Alkermes Stock Down 2.8 %
ALKS opened at $26.09 on Friday. The business’s 50-day simple moving average is $27.83 and its 200-day simple moving average is $25.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.61 and a current ratio of 2.99. Alkermes has a one year low of $22.06 and a one year high of $32.88. The stock has a market capitalization of $4.41 billion, a P/E ratio of 10.31, a price-to-earnings-growth ratio of 0.56 and a beta of 0.46.
Alkermes (NASDAQ:ALKS – Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. The company had revenue of $399.13 million for the quarter, compared to analyst estimates of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The firm’s revenue for the quarter was down 35.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.38 EPS. Analysts anticipate that Alkermes will post 2.36 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Alkermes
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
- Five stocks we like better than Alkermes
- What is the S&P 500 and How It is Distinct from Other Indexes
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Stock Sentiment Analysis: How it Works
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Hang Seng index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.